What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)

GIP stands for glucose-dependent insulinotropic polypeptide — a 42-amino-acid gut hormone secreted by K-cells in the upper small intestine in response to oral nutrients. Together with GLP-1 (glucagon-like peptide-1, secreted by L-cells of the distal small intestine and colon), GIP is one of the two canonical “incretin” hormones that account for the disproportionately greater insulin response the body mounts when glucose is given orally versus intravenously. The 2026 reason patients are searching for “GIP medical abbreviation” is that tirzepatide — the active ingredient in Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management and obstructive sleep apnea) — is the first FDA-approved dual GIP and GLP-1 receptor agonist. Both DailyMed labels state verbatim in §12.1: “Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.” [1][2]. SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) is the head-to-head phase 3 trial that demonstrated dual GIP+GLP-1 agonism produced greater HbA1c reduction AND greater weight loss than the single GLP-1 agonist semaglutide 1 mg [5]. The next-generation investigational triple agonist retatrutide layers glucagon-receptor agonism on top of GIP+GLP-1 (Jastreboff phase 2, NEJM 2023, PMID 37366315) — retatrutide is NOT FDA-approved as of 2026-05-09 [6]. This article walks through what GIP is, where the receptor lives, what the FDA labels actually say, and why dual agonism produces additive effects single-mechanism GLP-1 therapy cannot.

What does GIP stand for?

GIP = glucose-dependent insulinotropic polypeptide. It is a 42-amino-acid peptide hormone produced by enteroendocrine K-cells located primarily in the duodenum and proximal jejunum (the upper small intestine, where ingested food first enters after the stomach). The name itself describes the hormone's primary action: it stimulates insulin secretion (“insulinotropic”) in a manner that is dependent on the prevailing glucose concentration (“glucose-dependent”) — i.e., it acts strongly when blood glucose is high but does not drive insulin secretion when glucose is normal or low. This is the same glucose-dependence property that makes GLP-1 receptor agonists relatively safe with respect to hypoglycemia in non-diabetic patients.

Historical note: GIP was originally named “gastric inhibitory polypeptide” when it was first isolated in the early 1970s, based on its initial characterization as a hormone that inhibited gastric acid secretion in dogs. As the insulinotropic action became dominant in the human physiology literature, the abbreviation was retained but the expansion was reinterpreted to glucose-dependent insulinotropic polypeptide — which is what the 2026 endocrinology and pharmacology literature uses universally [3][4]. If you encounter a legacy textbook still using “gastric inhibitory polypeptide,” it's the same molecule.

Where GIP is made and what it does

GIP is secreted by intestinal K-cells in response to oral nutrients — particularly fats and carbohydrates — within minutes of food entering the small intestine. The hormone circulates briefly (its half-life is short, around 5-7 minutes, because it is rapidly degraded by the enzyme dipeptidyl peptidase-4, DPP-4) and binds to the GIP receptor, a class B G-protein-coupled receptor expressed on multiple tissues [3][4]:

• Pancreatic beta cells: GIP receptor activation stimulates insulin secretion in a glucose-dependent manner. This is the mechanism that accounts for most of the “incretin effect” observed after a meal — the disproportionately greater insulin response to oral vs intravenous glucose.
• Adipose tissue: GIP receptors are expressed on adipocytes. GIP modulates adipose tissue glucose uptake, lipogenesis, and lipid handling. The adipose-tissue effects of GIP are a topic of active research and are part of why dual-agonist tirzepatide may produce additive metabolic effects beyond what GLP-1 alone produces (more on this below).
• Bone: GIP receptors are expressed on osteoblasts (bone-forming cells). GIP appears to support bone formation and inhibit bone resorption, contributing to the post-meal bone-anabolic signal [4].
• Central nervous system: GIP receptors are expressed in regions of the hypothalamus and hindbrain involved in appetite and energy balance. The CNS effects of GIP receptor agonism are less well-characterized than those of GLP-1 but are part of why dual agonism produces additive weight loss [3][4].
• Pancreatic alpha cells: GIP also modestly stimulates glucagon secretion (in contrast to GLP-1, which inhibits glucagon). This alpha-cell effect is part of why GIP and GLP-1 have complementary rather than redundant actions when activated together [3].

Compared to GLP-1, GIP has substantially weaker effects on gastric emptying and satiety in healthy subjects — the delayed-gastric-emptying nausea that dominates the GLP-1 adverse-event profile is much less pronounced with GIP-receptor agonism alone. This difference matters clinically because it predicts that adding GIP-receptor agonism on top of GLP-1 should produce additive metabolic benefit without proportionally increasing the gastrointestinal side-effect burden — which is what SURPASS-2 actually showed in the head-to-head data [5].

GIP vs GLP-1 — sister incretin hormones

GIP and GLP-1 are the two canonical incretin hormones — gut peptides that signal “food has arrived” to the pancreas and stimulate the post-meal insulin response. They are sister hormones in function but are produced by different cells in different parts of the small intestine:

The post-meal kinetics differ in a way that matters physiologically: GIP rises first because nutrients reach the K-cell-rich upper small intestine first. GLP-1 rises slightly later as nutrients reach the more distal L-cells. Together they produce a coordinated insulinotropic signal across the meal that no single hormone reproduces alone. Drucker and Holst's decades of incretin physiology work form the foundation of the modern understanding [3][4].

For YMYL clarity: when patients ask “is Mounjaro a GLP-1?” the technically correct answer is no, it is a dual GIP and GLP-1 receptor agonist. Colloquially the entire drug class — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and the investigational pipeline — is often grouped together as “GLP-1s.” The colloquial usage is understandable but loses the most important pharmacological distinction in the class. See the dedicated discussion in our GLP-1 disambiguation FAQ hub for the broader brand-vs-molecule taxonomy.

Why tirzepatide activates BOTH receptors — the verbatim FDA labels

Section 12.1 of the FDA-approved DailyMed labels for both Mounjaro and Zepbound contains the canonical mechanism-of-action language. We reproduce both verbatim because the YMYL standard for medication content is to never paraphrase label text:

Mounjaro — §12.1 Mechanism of Action (verbatim)

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide is selective for human GIP and GLP-1 receptors. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.

Source: Mounjaro and Zepbound FDA prescribing information explained (DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, revised 4/2026) [1].

Zepbound — §12.1 Mechanism of Action (verbatim)

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide is selective for human GIP and GLP-1 receptors.

Source: DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, revised 4/2026 [2].

The two labels are using nearly identical text because they describe the same active molecule (tirzepatide) approved through two separate New Drug Applications for two different indications (T2D for Mounjaro; chronic weight management + OSA for Zepbound). The structural detail — a 39-amino-acid modified peptide with a C20 fatty diacid side chain that enables albumin binding for once-weekly dosing — is the chemistry that makes tirzepatide pharmacokinetically practical. The mechanism the FDA approved tirzepatide on, in both indications, is dual GIP and GLP-1 receptor agonism. That is the YMYL-anchored answer to “is Mounjaro a GLP-1?”

SURPASS-2 — what dual agonism actually delivers head-to-head

The clinical evidence that dual GIP+GLP-1 agonism is meaningfully superior to single GLP-1 agonism comes primarily from SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) [5] — an open-label, 40-week, phase 3 randomized trial of 1,879 adults with type 2 diabetes randomized to one of three doses of tirzepatide (5 mg, 10 mg, or 15 mg subcutaneously once weekly) or semaglutide 1 mg subcutaneously once weekly.

The primary endpoint was change in HbA1c at week 40. Key results [5]:

Tirzepatide at all three doses was superior to semaglutide 1 mg on both HbA1c and body weight — and the highest dose (15 mg) produced approximately twice the weight loss observed with semaglutide 1 mg over the same 40-week period, in the same trial, in directly comparable patients. The adverse event profile was similar between the two drugs (predominantly gastrointestinal, dose-dependent, mostly mild to moderate); SURPASS-2 did not show a worse tolerability profile for tirzepatide despite the additional GIP-receptor engagement [5].

SURPASS-2 is the canonical clinical evidence base for the dual-agonist concept: dual GIP+GLP-1 receptor agonism produces additive metabolic benefit over single GLP-1 agonism in head-to-head data, not just in mechanistic speculation. The specific comparator (semaglutide 1 mg, the T2D-approved Ozempic dose at the time) does limit the comparison — at the time of SURPASS-2, semaglutide had not yet been studied at 2 mg in T2D, and the 2.4 mg weight-management dose (Wegovy) had a separate development program. The full head-to-head deep dive is in our tirzepatide vs semaglutide head-to-head comparison, which walks through SURPASS-2, SURMOUNT-1, STEP-1, and the subsequent dose-comparison data.

Is Mounjaro/Zepbound a GLP-1?

This is the most-asked patient question about tirzepatide and it deserves a precise answer:

• Strict pharmacological classification: tirzepatide is a dual GIP and GLP-1 receptor agonist, not a pure GLP-1. The FDA-approved §12.1 mechanism-of-action language is unambiguous on this point [1][2].
• Casual / clinical usage: tirzepatide is often grouped with GLP-1 receptor agonists as part of “the GLP-1 class” or “GLP-1-based therapies.” This usage is common in patient conversations, payer formulary documents, and even some professional society materials. It is not technically accurate but it is widespread.
• Why the distinction matters: the dual agonism is the reason tirzepatide produces larger effect sizes than semaglutide head-to-head, and it is also the reason the safety profile differs in subtle ways (e.g., adipose-tissue and bone effects of GIP-receptor agonism that pure GLP-1 agonists do not produce). When a patient asks “is Mounjaro just like Wegovy?” the answer is no — they are different molecules with different receptor profiles, made by different manufacturers, with different effect sizes.

For the brand-vs-molecule disambiguation across all four major brand names (Wegovy, Ozempic, Zepbound, Mounjaro) plus the rest of the class (Saxenda, Victoza, Trulicity, Bydureon, Foundayo, Rybelsus), see our brand name cheat sheet and the GLP-1 same-as / disambiguation FAQ hub.

Why GIP receptor agonism alone doesn't work for weight loss

A reasonable question after reading the dual-agonism story is: if GIP is so important to the incretin effect, why isn't there a stand-alone GIP-receptor agonist for weight loss the way there is a stand-alone GLP-1 agonist (semaglutide)? The answer is that GIP-only receptor modulation has been studied — both as agonism and as antagonism — and the stand-alone weight-loss signal is modest at best [3][4].

The leading hypothesis for why GIP shines specifically in combination with GLP-1, rather than alone, has two parts:

1. GLP-1 provides the appetite/satiety arm. GLP-1's effects on hindbrain satiety circuits and gastric emptying are the dominant drivers of food intake reduction. GIP's effects on appetite are much weaker. Without GLP-1's satiety signal, GIP alone doesn't reduce caloric intake enough to drive substantial weight loss.
2. GIP provides the metabolic-flexibility arm. GIP's adipose-tissue effects, modest CNS effects, and direct beta-cell effects appear to be additive on top of GLP-1's satiety-driven weight loss — but they don't produce sufficient weight loss on their own. The dual agonism is genuinely synergistic in a way neither single arm reproduces.

This combination-only-works framing is why the next generation of obesity pharmacotherapy is moving toward multi-agonists rather than higher doses of single-mechanism drugs.

Next-generation: triple agonism (GIP + GLP-1 + glucagon)

Retatrutide (Eli Lilly internal designation LY3437943) is the canonical triple agonist — a single peptide that simultaneously activates GIP, GLP-1, and glucagon receptors. Glucagon is best known as a hyperglycemic counter-regulatory hormone (it raises blood glucose during fasting), but it also increases energy expenditure, stimulates lipolysis, and reduces hepatic fat. The glucagon-receptor arm of retatrutide is what allows the molecule to drive weight loss beyond what dual GIP+GLP-1 agonism produces — at the cost of additional safety complexity (you are simultaneously activating one hormone that raises glucose alongside two that lower it) [6].

The phase 2 trial in adults with obesity (Jastreboff et al., NEJM 2023, PMID 37366315) reported up to −24.2% body weight reduction at 48 weeks at the highest dose [6] — the largest weight loss any pharmacological obesity therapy had ever produced in a controlled trial at the time of publication. The first phase 3 readout, TRIUMPH-4 (December 11, 2025), reported ~28.7% mean weight loss at the highest dose in adults with obesity and knee osteoarthritis. The remaining TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 readouts are expected throughout 2026.

Retatrutide is investigational and NOT FDA-approved as of 2026-05-09. For the full evidence base, see our retatrutide triple-agonist evidence review. For the regulatory + access timeline (NDA filing window, FDA review duration, the 503A/503B compounding ineligibility, and the YMYL boundary on the “research peptide” grey market), see our retatrutide approval & access timeline 2026-27. For the broader pipeline of pre-approval drugs across every receptor combination, see our GLP-1 pipeline tracker.

How dual GIP/GLP-1 fits in the obesity drug landscape

The GIP receptor sits at the center of a clear receptor-stacking hierarchy in obesity pharmacology — each added receptor target produces approximately additive weight loss in head-to-head data:

The GIP-receptor arm is responsible for approximately the delta between the Wegovy line and the Zepbound line — i.e., adding GIP-receptor agonism on top of GLP-1 produces roughly 5-6 additional percentage points of weight loss in the highest-effect-size head-to-head comparisons. That is the clinical magnitude that makes GIP receptor agonism a first-class component of modern obesity pharmacology rather than a footnote.

What this means for patients choosing between drugs

For patients deciding between Wegovy and Zepbound, the receptor-mechanism difference is the single most important factor in expected effect size. The verbatim FDA-approved labels classify these as different drug classes (Wegovy = GLP-1 RA; Zepbound = dual GIP/GLP-1 RA) [1][2], and the trial data supports the labels: Zepbound at the maximum 15 mg dose produces meaningfully greater weight loss than Wegovy at the maximum 2.4 mg dose, in head-to-head data and in cross-trial comparison [5]. That said, the choice is rarely just about effect size — payer coverage, injection device preference, GI tolerability, and clinical contraindications all matter. The relevant decision flows are walked through in our GLP-1 decision quiz.

For patients deciding between Mounjaro (T2D-labeled tirzepatide) and Zepbound (obesity-labeled tirzepatide), the active molecule is identical — same dual GIP/GLP-1 receptor agonism, same dose-titration schedule, same boxed warning on thyroid C-cell tumors. The difference is the FDA-approved indication and the insurance pathway. See Mounjaro and Zepbound prescribing information explained for the verbatim §1 indication language and the side-by-side label comparison.

Bottom line

GIP — glucose-dependent insulinotropic polypeptide — is one of the two canonical incretin hormones (the other is GLP-1). Both are gut hormones secreted in response to food, both stimulate glucose-dependent insulin secretion, and both are now therapeutic targets in modern obesity and diabetes pharmacology. The clinical importance of GIP in 2026 is that tirzepatide — sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea — is the first FDA-approved dual GIP and GLP-1 receptor agonist. The §12.1 mechanism-of-action language in both DailyMed labels states this verbatim. Head-to-head data from SURPASS-2 demonstrates that dual GIP+GLP-1 agonism produces greater HbA1c reduction and greater weight loss than single GLP-1 agonism [5]. The next-generation triple agonist retatrutide adds glucagon-receptor agonism on top of GIP+GLP-1 (phase 2 PMID 37366315) [6]; retatrutide is investigational and not FDA-approved. For the patient asking “is Mounjaro a GLP-1?”, the precise answer is no — it is a dual GIP and GLP-1 receptor agonist, and the GIP-receptor contribution is what makes tirzepatide's effect size larger than semaglutide's in head-to-head trials.

Related research

For the verbatim FDA-approved labels for Mounjaro and Zepbound — including the §1 indications, §2 dose titration, §5 warnings (boxed and otherwise), and §12.1 mechanism — see our Mounjaro and Zepbound FDA prescribing information explained. For the head-to-head efficacy comparison between tirzepatide (dual GIP/GLP-1) and semaglutide (single GLP-1) across SURPASS-2, SURMOUNT-1, and STEP-1, see our tirzepatide vs semaglutide head-to-head. For the next-generation triple agonist evidence base (GIP + GLP-1 + glucagon), see our retatrutide triple-agonist evidence review and the retatrutide approval & access timeline 2026-27. For the GLP-1 + amylin combination evidence base, see our CagriSema REDEFINE trial deep-dive. For the brand-vs-molecule taxonomy (which brand has which active ingredient, made by which manufacturer, for which FDA-approved indication), see our brand name cheat sheet and the GLP-1 same-as / disambiguation FAQ hub. For the chronological 2026 view of every approval and readout across the entire incretin class, see our newest GLP-1 drugs (2026) reference.